T
Thomas E. Moon
Researcher at University of Arizona
Publications - 101
Citations - 8529
Thomas E. Moon is an academic researcher from University of Arizona. The author has contributed to research in topics: Cancer & Combination chemotherapy. The author has an hindex of 43, co-authored 101 publications receiving 8313 citations. Previous affiliations of Thomas E. Moon include University of Texas Health Science Center at Houston & Southern Research Institute.
Papers
More filters
Journal ArticleDOI
A clinical trial of immunosuppressive therapy for myocarditis
Jay W. Mason,John B. O'Connell,Ahvie Herskowitz,Noel R. Rose,Bruce M. McManus,Margaret E. Billingham,Thomas E. Moon +6 more
TL;DR: The results do not support routine treatment of myocarditis with immunosuppressive drugs, but long-term mortality was high and patients with a vigorous inflammatory response had less severe disease.
Journal ArticleDOI
Quantitation of Differential Sensitivity of Human-Tumor Stem Cells to Anticancer Drugs
Sydney E. Salmon,Anne W. Hamburger,Soehnlen B,Brian G.M. Durie,David S. Alberts,Thomas E. Moon +5 more
TL;DR: An in vitro tumor-colony assay developed to measure sensitity of human-tumor stem cells to anticancer drugs shows sufficient promise to warrant larger-scale testing to determine its efficacy for selection of new agents and individualized cancer chemotherapy regimens.
Journal ArticleDOI
Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma
Eugene M. McKelvey,Jeffrey A. Gottlieb,Henry E. Wilson,Arthur Haut,Robert W. Talley,Ronald Stephens,Montague Lane,Jess F. Gamble,Stephen E. Jones,Grozea Pn,Jordon Gutterman,Charles A. Coltman,Thomas E. Moon +12 more
TL;DR: Combination chemotherapy with CHOP and HOP was used as treatment for patients with pathologically staged, advanced non‐Hodgkin's lymphoma, and patients with nodular lymphoma had higher rates of complete remission than their counterparts with diffuse lymphoma.
Journal ArticleDOI
Dose response evaluation of adriamycin in human neoplasia
Robert M. O'Bryan,Laurence H. Baker,J. E. Gottlieb,Saul E. Rivkin,Stanley P. Balcerzak,G. N. Grumet,Sydney E. Salmon,Thomas E. Moon,B. Hoogstraten +8 more
TL;DR: There were no statistically significant differences in remission rates, durations of remission, or toxicities in the dose schedules studied, and unless rapid remission induction is urgent, the recommend 60 mg/m2 X four doses and measurement of myocardial function if treatment is to continue.
Journal ArticleDOI
The intergroup rhabdomyosarcoma study. A preliminary report
Harold M. Maurer,Thomas E. Moon,Milton H. Donaldson,Carlos H. Fernandez,Edmund A. Gehan,Denman Hammond,Daniel M. Hays,Walter Lawrence,William A. Newton,Abdelsalam H. Ragab,Beverly Raney,Edward H. Soule,W. W. Sutow,Melvin Tefft +13 more
TL;DR: There is no indication as yet that one treatment regimen is superior to the other in the Intergroup Rhabdomyosarcoma Study, and over 85% of patients on either treatment have no evidence of disease and 90% are still alive.